Healthcare resource use and costs associated with episodes of laboratory confirmed invasive pneumococcal disease in adults in Finland 2016–2022

IF 4.5 3区医学 Q2 IMMUNOLOGY

Vaccine Pub Date : 2025-06-20 DOI:10.1016/j.vaccine.2025.127398

Maarit J. Korhonen , Mari Pölkki , Veli-Jukka Anttila , Peter Klemets , Essi J. Peltonen , Timo Purmonen , Minna Vehkala , Jenni Kononoff

{"title":"Healthcare resource use and costs associated with episodes of laboratory confirmed invasive pneumococcal disease in adults in Finland 2016–2022","authors":"Maarit J. Korhonen , Mari Pölkki , Veli-Jukka Anttila , Peter Klemets , Essi J. Peltonen , Timo Purmonen , Minna Vehkala , Jenni Kononoff","doi":"10.1016/j.vaccine.2025.127398","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div><em>Streptococcus pneumoniae</em> is a common mortality and morbidity causing pathogen worldwide which can lead to both invasive and noninvasive pneumococcal disease. Invasive pneumococcal disease (IPD) is a severe form of pneumococcal infection manifesting, for example, as bacteremia, sepsis, or meningitis. This study evaluated the clinical and economic burden caused by laboratory confirmed IPD in the population aged ≥18 years in Finland 2016–2022.</div></div><div><h3>Methods</h3><div>IPD episodes were identified from the National Infectious Disease Register. Healthcare resource use (HCRU) was obtained from the Finnish care registers and linked to each 90-day episode. Case-fatality was determined within 30 days since the first <em>S. pneumoniae</em> culture. HCRU, including hospitalizations and outpatient visits, was valued according to the national healthcare unit costs. The direct costs associated with HCRU, adjusted to the 2023 level, were calculated per episode and per year, and stratified by patient's age.</div></div><div><h3>Results</h3><div>Overall, 4018 IPD episodes were identified, with the median age of patients being 67 years. Meningitis was identified for 2.9 % of the episodes. Case-fatality was 9.7 % in all adults and increased steeply with age, from 3.2 % in 18–49-year-olds to 26.7 % in ≥85-year-olds. The average costs per episode were €9118 (95 % confidence interval [CI] €8802-€9419), with the highest costs (€9953; 95 % CI €9242-€10,562) observed in the 65–74-year-olds. In all adults, the mean total annual costs associated with IPD episodes were €5.23 million (95 % CI €3.66–€6.57 million). Inpatient care comprised 94 % of the total costs. In adults aged 65 and older, serotype coverage for pneumococcal conjugate vaccines PCV13, PCV20 and PCV21(V116) was 47.5 %, 66.5 %, 77.0 %, respectively.</div></div><div><h3>Conclusions</h3><div>This study demonstrates the significant burden of IPD in the Finnish adult population. Wider vaccination against <em>S. pneumoniae</em> has the potential to substantially reduce the health and economic burden associated with pneumococcal diseases especially among older adults.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"61 ","pages":"Article 127398"},"PeriodicalIF":4.5000,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vaccine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0264410X25006954","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Streptococcus pneumoniae is a common mortality and morbidity causing pathogen worldwide which can lead to both invasive and noninvasive pneumococcal disease. Invasive pneumococcal disease (IPD) is a severe form of pneumococcal infection manifesting, for example, as bacteremia, sepsis, or meningitis. This study evaluated the clinical and economic burden caused by laboratory confirmed IPD in the population aged ≥18 years in Finland 2016–2022.

Methods

IPD episodes were identified from the National Infectious Disease Register. Healthcare resource use (HCRU) was obtained from the Finnish care registers and linked to each 90-day episode. Case-fatality was determined within 30 days since the first S. pneumoniae culture. HCRU, including hospitalizations and outpatient visits, was valued according to the national healthcare unit costs. The direct costs associated with HCRU, adjusted to the 2023 level, were calculated per episode and per year, and stratified by patient's age.

Results

Overall, 4018 IPD episodes were identified, with the median age of patients being 67 years. Meningitis was identified for 2.9 % of the episodes. Case-fatality was 9.7 % in all adults and increased steeply with age, from 3.2 % in 18–49-year-olds to 26.7 % in ≥85-year-olds. The average costs per episode were €9118 (95 % confidence interval [CI] €8802-€9419), with the highest costs (€9953; 95 % CI €9242-€10,562) observed in the 65–74-year-olds. In all adults, the mean total annual costs associated with IPD episodes were €5.23 million (95 % CI €3.66–€6.57 million). Inpatient care comprised 94 % of the total costs. In adults aged 65 and older, serotype coverage for pneumococcal conjugate vaccines PCV13, PCV20 and PCV21(V116) was 47.5 %, 66.5 %, 77.0 %, respectively.

Conclusions

This study demonstrates the significant burden of IPD in the Finnish adult population. Wider vaccination against S. pneumoniae has the potential to substantially reduce the health and economic burden associated with pneumococcal diseases especially among older adults.

查看原文本刊更多论文

2016-2022年芬兰成人实验室确认的侵袭性肺炎球菌疾病发作相关的医疗资源使用和成本

背景肺炎链球菌是世界范围内常见的致死率和致病性病原体，可导致侵袭性和非侵袭性肺炎球菌疾病。侵袭性肺炎球菌病（IPD）是肺炎球菌感染的一种严重形式，表现为菌血症、败血症或脑膜炎。本研究评估了芬兰2016-2022年年龄≥18岁人群实验室确诊IPD造成的临床和经济负担。方法从国家传染病登记册中确定sipd发作。医疗资源使用（HCRU）数据来自芬兰的医疗登记，并与每90天的发作相关联。在首次肺炎链球菌培养后30天内确定病死率。HCRU，包括住院和门诊，是根据国家卫生保健单位费用计算的。与HCRU相关的直接费用调整到2023年的水平，计算每一次和每年的费用，并按患者年龄分层。结果共发现4018例IPD发作，患者中位年龄为67岁。2.9%的病例为脑膜炎。所有成年人的病死率为9.7%，并且随着年龄的增长而急剧增加，从18 - 49岁的3.2%增加到≥85岁的26.7%。平均每集成本为9118欧元（95%置信区间[CI] 8802- 9419欧元），最高成本为9953欧元；95%（9242- 10562欧元）在65 - 74岁的人群中观察到。在所有成年人中，与IPD发作相关的平均年总费用为523万欧元（95% CI为366 - 657万欧元）。住院治疗费用占总费用的94%。在65岁及以上的成年人中，肺炎球菌结合疫苗PCV13、PCV20和PCV21（V116）的血清型覆盖率分别为47.5%、66.5%和77.0%。结论：本研究表明芬兰成年人患IPD的负担显著。广泛接种肺炎链球菌疫苗有可能大大减轻与肺炎球菌疾病相关的健康和经济负担，特别是在老年人中。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Vaccine 医学-免疫学

CiteScore

8.70

自引率

5.50%

发文量

992

审稿时长

131 days

期刊介绍： Vaccine is unique in publishing the highest quality science across all disciplines relevant to the field of vaccinology - all original article submissions across basic and clinical research, vaccine manufacturing, history, public policy, behavioral science and ethics, social sciences, safety, and many other related areas are welcomed. The submission categories as given in the Guide for Authors indicate where we receive the most papers. Papers outside these major areas are also welcome and authors are encouraged to contact us with specific questions.